Is the CSL share price set to take off in December?

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

The CSL Limited (ASX: CSL) share price leapt 7% in November, and December looks like it could bring more joy. Experts are generally bullish on the Aussie biotechnology giant.

Particularly on the back of the company’s Hemgenix treatment, which recently received US Food and Drug Administration (FDA) approval. The gene therapy is designed to treat hemophilia B.

It has also reportedly been crowned the world’s most expensive treatment. A single dose is said to command a US$3.5 million price tag.

Right now, the CSL share price is $299.72.

Let’s take a look at what brokers are saying about the S&P/ASX 200 Index (ASX: XJO) healthcare giant.

What might the future hold for the CSL share price?

CSL appears to be a favourite among brokers and experts right now, with some predicting its share price to leap as high as $343.

That’s the prediction put forward by Macquarie, as my Fool colleague James reports. The top broker has a buy rating on the stock and expects Hemgenix’s early 2023 launch to boost the company’s earnings.

Citi is also hopeful for CSL, slapping the share with a buy rating and a $340 price target.

Not all brokers are so enthusiastic, however. Goldman Sachs’ most recent forecast, from early November, tips the CSL share price to fall to $291.

It’s worth noting that experts apparently aren’t tipping the company’s bottom line to be immediately buoyed by Hemgenix’s launch. Indeed, CSL chief commercial officer Bill Campbell recently told investors “it will take a little bit of time for questions to be answered in the commercial space”, the Australian Financial Review reports.

Looking beyond CSL and to the healthcare sector more broadly, Janus Henderson portfolio manager Andy Acker recently wrote, per Livewire:

[E]ven if major economies enter a recession in 2023, we believe the healthcare sector could offer investors some safe harbour. In the past, the sector has outperformed in the months leading up to and during economic downturns; the same could hold true again.

Additionally, Morgans equity analyst Anna Milne is said to like the prospects of the company’s Seqirus vaccine in the upcoming flu season and its recently-acquired Vifor iron deficiency therapy business. Morgans expects the CSL share price to lift to $327, according to Livewire.

All in all, many experts appear to believe December could be a good time to buy CSL stock ahead of an expected share price surge.

The post Is the CSL share price set to take off in December? appeared first on The Motley Fool Australia.

FREE Investing Guide for Beginners

Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…

For over a decade, we’ve been helping everyday Aussies get started on their journey.

And to help even more people cut through some of the confusion “experts’” seem to want to perpetuate – we’ve created a brand-new “how to” guide.

Yes, Claim my FREE copy!
*Returns as of November 7 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];[property] = defaultValue;

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);

More reading

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s